Literature DB >> 18783741

Challenges in the management of rheumatoid arthritis in developing countries.

Girish M Mody1, Mario H Cardiel.   

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease which is characterized by chronic inflammation of the joints. Patients experience chronic pain and suffering, and increasing disability; without treatment, life expectancy is reduced. It is imperative to identify patients early so that control of inflammation can prevent joint destruction and disability. Although great advances have been made in the developed nations, early diagnosis remains a great challenge for developing countries during the Bone and Joint Decade (2000-2010) and beyond. Developing countries face important and competitive social, economic, health- and poverty-related issues, and this frequently results in chronic diseases such as RA being forgotten in health priorities when urgent health needs are considered in an environment with poor education and scarce resources. Epidemiological studies in developing countries show a lower but still important prevalence in different regions when compared to that in Caucasians. It seems that the severity of RA varies among different ethnic groups, and probably starts at a younger age in developing countries. Practising rheumatologists in these regions need to take into account several important problems that include suboptimal undergraduate education, inadequate diagnosis, late referrals, lack of human and technical resources, poor access to rheumatologists, and some deficiencies in drug availability. Infections are very important in RA, and special care is needed in developing countries as some endemic infections include tuberculosis, human immunodeficiency virus (HIV), hepatitis B, and hepatitis C. These infections should be carefully taken into account when medications are prescribed and monitored. This chapter presents published information covering the main challenges faced in these environments, and suggests strategies to overcome these important problems in RA management.

Entities:  

Mesh:

Year:  2008        PMID: 18783741     DOI: 10.1016/j.berh.2008.04.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  29 in total

Review 1.  Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes.

Authors:  Asma Arabi; Rola El Rassi; Ghada El-Hajj Fuleihan
Journal:  Nat Rev Endocrinol       Date:  2010-10       Impact factor: 43.330

2.  Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.

Authors:  Karima Benbouazza; Bahia Benchekroun; Hanan Rkain; Bouchra Amine; Fatiha Bzami; Leila Benbrahim; Ouafa Atouf; Malika Essakalli; Redouane Abouqal; Maxime Dougados; Najia Hajjaj-Hassouni
Journal:  BMC Musculoskelet Disord       Date:  2011-11-23       Impact factor: 2.362

Review 3.  Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects.

Authors:  Mahendra Kumar Verma; Kota Sobha
Journal:  Inflamm Res       Date:  2015-07-07       Impact factor: 4.575

4.  Cardiovascular risk factors' behavior during the early stages of the disease, in Hispanic rheumatoid arthritis patients: a cohort study.

Authors:  Irazú Contreras-Yáñez; Guillermo Guaracha-Basáñez; Virginia Pascual-Ramos
Journal:  Rheumatol Int       Date:  2019-10-12       Impact factor: 2.631

Review 5.  The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists.

Authors:  Adel Alawadhi; Khaldoon Alawneh; Zeyad Ahmed Alzahrani
Journal:  Clin Rheumatol       Date:  2012-08-09       Impact factor: 2.980

6.  Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.

Authors:  Diana I Pérez-Román; Ana B Ortiz-Haro; Emmanuel Ruiz-Medrano; Irazú Contreras-Yáñez; Virginia Pascual-Ramos
Journal:  Rheumatol Int       Date:  2017-12-20       Impact factor: 2.631

7.  Cumulative disease activity predicts incidental hearing impairment in patients with rheumatoid arthritis (RA).

Authors:  Virginia Pascual-Ramos; Irazú Contreras-Yáñez; Paula Rivera-Hoyos; Lorena Enríquez; Jaqueline Ramírez-Anguiano
Journal:  Clin Rheumatol       Date:  2014-01-18       Impact factor: 2.980

8.  Adverse outcomes following hand surgery in patients with rheumatoid arthritis.

Authors:  Victor M Menchaca-Tapia; Elizabeth M Rodríguez; Irazú Contreras-Yáñez; Martin Iglesias-Morales; Virginia Pascual-Ramos
Journal:  Plast Surg (Oakv)       Date:  2016-05-27       Impact factor: 0.947

9.  Maintenance of Remission with Etanercept-DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis.

Authors:  Hassan Bassiouni; Catherine Elizabeth Spargo; Bonnie Vlahos; Heather E Jones; Ron Pedersen; Khalid Shirazy
Journal:  Rheumatol Ther       Date:  2018-02-26

10.  Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.

Authors:  Virginia Pascual-Ramos; Irazú Contreras-Yáñez; Antonio R Villa; Javier Cabiedes; Marina Rull-Gabayet
Journal:  Arthritis Res Ther       Date:  2009-02-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.